Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation

Trial Profile

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 803 (Primary) ; ALT 803 (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2020.
    • 27 Aug 2019 Planned End Date changed from 1 Jun 2020 to 1 Oct 2019.
    • 06 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top